TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01660958

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNP
Description: The formulation of the multiple micronutrient powder (MNP) was based on low micronutrient intake, low bioavailability of iron and zinc in the Indian diet, and current World Health Organization (WHO)and Indian recommendations regarding fortification and age-specific nutrient requirements. The MNP formulations were produced by a certified company in India and include: Iron, Vitamin A, Vitamin C, Folic Acid, Zinc, Vitamin B12 Vitamin B2, plus filler (maltodextrin). Placebo included riboflavin and maltodextrin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNP
Description: The formulation of the multiple micronutrient powder (MNP) was based on low micronutrient intake, low bioavailability of iron and zinc in the Indian diet, and current World Health Organization (WHO)and Indian recommendations regarding fortification and age-specific nutrient requirements. The MNP formulations were produced by a certified company in India and include: Iron, Vitamin A, Vitamin C, Folic Acid, Zinc, Vitamin B12 Vitamin B2, plus filler (maltodextrin). Placebo included riboflavin and maltodextrin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNP
Description: The formulation of the multiple micronutrient powder (MNP) was based on low micronutrient intake, low bioavailability of iron and zinc in the Indian diet, and current World Health Organization (WHO)and Indian recommendations regarding fortification and age-specific nutrient requirements. The MNP formulations were produced by a certified company in India and include: Iron, Vitamin A, Vitamin C, Folic Acid, Zinc, Vitamin B12 Vitamin B2, plus filler (maltodextrin). Placebo included riboflavin and maltodextrin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNP
Description: The formulation of the multiple micronutrient powder (MNP) was based on low micronutrient intake, low bioavailability of iron and zinc in the Indian diet, and current World Health Organization (WHO)and Indian recommendations regarding fortification and age-specific nutrient requirements. The MNP formulations were produced by a certified company in India and include: Iron, Vitamin A, Vitamin C, Folic Acid, Zinc, Vitamin B12 Vitamin B2, plus filler (maltodextrin). Placebo included riboflavin and maltodextrin.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Learning
Description: • Infant will benefit from interventions that are based on responsive parenting, whereby caregivers respond to children's cues, provide opportunities for exploration, and engage in nurturant and reciprocal communication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Learning
Description: • Infant will benefit from interventions that are based on responsive parenting, whereby caregivers respond to children's cues, provide opportunities for exploration, and engage in nurturant and reciprocal communication.
Study: NCT02809833

Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab must be selected by the treating physician in advance of the study and will be not provided by the Sponsor. The dose/regimen are at the discretion of the prescriber. However, tocilizumab in the SmPC is specified as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion at 4-week intervals.
Study: NCT01076257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Constraint-induced Movement Therapy
Description: Home based CIT~1. Restriction of the less affected limb~2. Intensive practice using affected limb~3. Positive experience~4. Functional task (task)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modified Constraint-induced Movement Therapy
Description: Home based CIT~1. Restriction of the less affected limb~2. Intensive practice using affected limb~3. Positive experience~4. Functional task (task)
Study: NCT00503204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: oral capsule
Study: NCT04583371

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MECHANICAL PULMONARY HYPERINFLUATION
Description: For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique. In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the same way as baseline aspiration, in assisted-controlled pressure ventilation, increasing 10 cmH2O in inspiratory pressure and, in ventilatory mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, observing the peak that cannot exceed 40 cmH2O in both ventilation modes, and then three aspirations will be performed for 15 seconds and with an interval of 30 seconds.
Study: NCT04264533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC
Description: 12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
Study: NCT03060122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIN
Description: The InterX device will be applied by a trained therapist along the course of the dermatomes in the affected area, paying special attention to the location of major cutaneous nerves ensuring optimal treatment points are identified and treated within the neurologically related area.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIN
Description: The InterX device will be applied by a trained therapist along the course of the dermatomes in the affected area, paying special attention to the location of major cutaneous nerves ensuring optimal treatment points are identified and treated within the neurologically related area.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham CES
Description: The sham CES is identical to the regular device but ear clips will emit a dose at 100 mA, a sub-sensory level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES
Description: Cranial Electrical Stimulation (CES) Alpha-Stim is a noninvasive medical treatment device that delivers a microcurrent (100 to 500 microamperes) via ear clip electrodes connected to a handheld device.
Study: NCT04264533

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Water for Injection
Description: 50ml sterile water for injection will be infused in the placebo comparator group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
Study: NCT01197287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAK423A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAK423A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAK423A
Study: NCT02889367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir 100 mg
Description: Participants will receive odalasvir 2\*50 mg tablet, orally once on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir 500 mg
Description: Participants will receive odalasvir 10\*50 mg tablet, orally once on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (Up to maximum 1000 mg)
Description: Participants will receive odalasvir to be decided up to maximum of 20\*50 mg tablet, orally once on Day 1.
Study: NCT00358540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Dosing of sarcoma subjects with eltrombopag after treatment with Adriamycin and Ifosfamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Dosing of sarcoma subjects with eltrombopag after treatment with Adriamycin and Ifosfamide.
Study: NCT04679415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: hzVSF-v13 40 mg/mL in a 5 mL vial Frequency: Dose at Day 1, 3, 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: hzVSF-v13 40 mg/mL in a 5 mL vial Frequency: Dose at Day 1, 3, 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal saline solution)
Description: Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7
Study: NCT03370172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAX 888
Description: Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1, 2, 3 on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAX 888
Description: Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1, 2, 3 on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAX 888
Description: Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1, 2, 3 on Day 0.
Study: NCT03500445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab (16 mg/kg) will be administered as an IV infusion:~* Cycle 1-2: 16 mg/kg weekly~* Cycles 3-8: 16 mg/kg IV infusion every 2 weeks~* Cycles 9-24: 16 mg/kg IV infusion Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be given as an IV infusion over 30 minutes:~* Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8, 9 of cycle 1) will be allowed at the treating physician's discretion.~* Cycle 2-9: 36 mg/m2 (or best tolerated dose) Days 1, 2, 8, 9, 15 and 16~* Cycles 9-24: 36 mg/m2 (or best tolerated dose) Days 1, 2, 15 and 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be taken orally as follows:~• Cycles 1-24: 25 mg (or best tolerated dose) PO Days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered prior to carfilzomib (on days that they coincide), as follows:~* Cycles 1-9: 40 mg PO (subjects ≤ 75 years) or 20 mg PO (subjects ≥ 75 years) per week~* Cycles 9-24: 20 mg PO per week~During weeks when daratumumab is given: 40 mg dexamethasone weekly, 20 mg prior to daratumumab infusion and 20 mg PO the day after~During weeks with no daratumumab, single dose of 20 mg on day 1
Study: NCT04856514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS
Description: 16 week telehealth intervention; parallel teen and parent/caregiver groups; 90 minutes each week.
Study: NCT04241614

Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study: NCT03285243

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Monochromatic blue light
Description: Exposure to monochromatic light for the first 30 minutes in the recovery period after anesthesia to assess incidence of emergence delirium as noted by the PAED scale

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monochromatic blue light
Description: Exposure to monochromatic light for the first 30 minutes in the recovery period after anesthesia to assess incidence of emergence delirium as noted by the PAED scale
Study: NCT04467580

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: abdominal [18F]FDG PET/CT
Description: Patients will have within a maximum period of 15 days before the surgery (resection of intestinal stenosis), records by MRI and by digital PET/CT with low injected activity of \[18F\]FDG, focused on the abdomen, the MRI will be performed maximum 30 days before the intervention (if available and performed according to the procedure for the study, it will not be repeated for the study).
Study: NCT00131846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazide diuretics
Description: Any dosage, frequency, and duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No diuretics
Description: Any antihypertensive regimen other than diuretics
Study: NCT05536661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preservative free hyaluronic acid artificial tear
Description: Ocular lubricant
Study: NCT02885571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SomnoDent Flex with DentiTrac

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SomnoDent Flex with DentiTrac
Study: NCT02282683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months
Study: NCT02486757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized progesterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal estradiol
Study: NCT04314960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation device (NESS L300Plus, Bioness, Valencia, CA)
Description: Functional electrical stimulation (FES) is the application of high-intensity intermittent electrical stimuli to generate muscle contractions that may bypass spinal and supraspinal inhibition, and which is coupled with a functional task such as gait. Gait training will be conducted on a treadmill.
Study: NCT01510678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Fruits and Vegetables
Description: Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F\&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables. Both parent and child will self-monitor these behaviors. As one barrier to consuming F\&Vs is perceived cost of these foods, information regarding lower-cost options for F\&Vs will be included in the manual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decrease Snack Foods
Description: This condition will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to \< 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
Study: NCT01731938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant (FS) Grifols
Description: Fibrin Sealant (FS) Grifols: The maximum total volume of FS Grifols allowed to be applied at the target bleeding site by dripping or spraying was approximately 12 mL (equivalent to the full content of 2 FS Grifols kits).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel®
Description: Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
Study: NCT01510678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Fruits and Vegetables and Decrease Snack Foods
Description: Will combine the goals of the increase and decrease conditions.
Study: NCT04600908

Intervention type: OTHER
Intervention: Characteristics of accidents
Description: informations about commuting accidents were recorded either during an occupational medicine consultation or by the medical service after reception of the medical certificate and the administrative declaration
Study: NCT05644366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural Control Balance Assessment
Description: Postural Stability Testing Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks.
Study: NCT01078766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIMT+HABIT
Description: The daily schedule included one hour of constraining the functional arm with intensive activation of the hemi-paretic arm and then 5 hours of various structured, intensive bimanual functional activities,
Study: NCT02392182

Intervention type: OTHER
Intervention: Fiberoptic bronchoscopy
Description: All subjects will undergo a research fiberoptic bronchoscopy under moderate conscious sedation. There is no randomization
Study: NCT03517631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: shRNA-modified CD34+ cells
Description: Infusion of CD34+ cells transduced with shRNAs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: shRNA-modified CD34+ cells
Description: Infusion of CD34+ cells transduced with shRNAs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: shRNA-modified CD34+ cells
Description: Infusion of CD34+ cells transduced with shRNAs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose busulfan preconditioning
Description: A single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan preconditioning
Description: A single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
Study: NCT03647813

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Patients received three irradiations of laser at ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same laser protocol was followed but with the device switched off.
Study: NCT02773953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T4PTelemonitoring
Description: addition of a Telemonitoring unit on the CPAP line to standard care.
Study: NCT04689776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-Task Training
Description: The programs are based on dual-task trainings which contain cognitive training and exercise simultaneously. For physical exercise, we will design the programs that involve balance or strength training components in the aerobic exercises. In terms of cognitive training, we will design self-made teaching aids and board games to train different domains of cognitive functions. We plan to assess the participants before and after the intervention programs. We expect that elders receiving dual-task training will improve on outcome measures, and the group with more frequency will have better performance. The results of the study will provide evidence of interventions for elderly with cognitive decline, thereby reducing the burden on their caregivers and the cost of medical resource.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-Task Training
Description: The programs are based on dual-task trainings which contain cognitive training and exercise simultaneously. For physical exercise, we will design the programs that involve balance or strength training components in the aerobic exercises. In terms of cognitive training, we will design self-made teaching aids and board games to train different domains of cognitive functions. We plan to assess the participants before and after the intervention programs. We expect that elders receiving dual-task training will improve on outcome measures, and the group with more frequency will have better performance. The results of the study will provide evidence of interventions for elderly with cognitive decline, thereby reducing the burden on their caregivers and the cost of medical resource.
Study: NCT04228185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy
Description: Comparison of banded and not-banded sleeve gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: Comparison of banded and not-banded sleeve gastrectomy
Study: NCT04150380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG; ATCC strain 53103; CRMTS #11272; PTS #3766)
Description: See arm descriptions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm descriptions
Study: NCT01610635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced versus standard intervals between blood donations
Description: Over a period of two years participants will be invited to give blood either at usual donation intervals or more frequently. Men will be invited to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks.
Study: NCT02773953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP treatment for treatment of obstructive sleep apnea syndrome

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP treatment for treatment of obstructive sleep apnea syndrome
Study: NCT01256294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Tacrolimus
Description: Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic Tacrolimus
Description: Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branded Tacrolimus
Description: Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Branded Tacrolimus
Description: Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
Study: NCT04681352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Octave-Ultherapy treatment
Description: Micro-focused ultrasound delivered below the surface of the skin.
Study: NCT03625843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness exercises
Study: NCT03220451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesive elastic taping
Description: Adhesive elastic taping placed around a pressure ulcer, according to a planned placement technique
Study: NCT01643772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride
Description: The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride
Description: The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride
Description: The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride
Description: The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.